Zoll Defibrillator Sales Growth, Upcoming Public AED Entry Buoy Stock In July
This article was originally published in The Gray Sheet
Zoll Medical's upcoming entry into the public access automated external defibrillator (AED) market, coupled with revived sales growth in its third fiscal quarter, helped the firm's stock jump ahead 33% in July. The issue closed at $36.45, up $9 for the month.
You may also be interested in...
The reliance on hospitalization for angina as a safety endpoint in the clinical trials of CardioGenesis' Eclipse PMR (percutaneous myocardial revascularization) device masked the rate of significant adverse events related to the procedure, according to FDA's Circulatory System Devices Panel.
Zoll Medical is expecting the smaller size of its biphasic M-Series automated external defibrillator (AED) combined with FDA-cleared superiority claims over competing devices to result in a sizable chunk of the public access defibrillator market.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.